Advertisement
Singapore markets closed

  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     

  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • FTSE 100

    8,124.60
    +45.74 (+0.57%)
     

  • Bitcoin USD

    63,886.91
    +794.15 (+1.26%)
     

  • CMC Crypto 200

    1,384.22
    -12.32 (-0.88%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • Dow

    38,085.80
    -375.12 (-0.98%)
     

  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     

  • Gold

    2,359.70
    +17.20 (+0.73%)
     

  • Crude Oil

    84.22
    +0.65 (+0.78%)
     

  • 10-Yr Bond

    4.6610
    -0.0450 (-0.96%)
     

  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     

  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     

  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Biogen shares halted as FDA advisory panel meets to discuss Alzheimer's drug

Investing.com
·1-min read

Investing.com -- Biogen Inc. (NASDAQ:BIIB) announced that the Nasdaq (NASDAQ:NDAQ) exchange had halted trading of its stock on Friday.

The move comes as advisors to the U.S. Food and Drug Administration meet to review the potential traditional approval of an Alzheimer's disease drug made by the biotech company and partner Eisai.

On Wednesday, data from a late-stage trial released by the FDA showed that the treatment, known as Leqembi, helped stem the progression of cognitive decline in patients suffering from Alzheimer's disease.

The documents also suggested that safety worries would most likely not hurt the chances that the drug will be given the green light from regulators.

ADVERTISEMENT

The FDA is expected to deliver a formal decision by July 6.

Related Articles

Biogen shares halted as FDA advisory panel meets to discuss Alzheimer's drug

Canaccord says eVTOL TAM could be worth almost $58bn by 2033

U.S. House panel to take up aviation reform measure